FDA Proposes to Close Large-Scale GLP-1 Compounding for Good, Targeting the 503B Outsourcing Pathway

Key takeaways

• On 30 April 2026, the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List, citing no clinical need for large-scale outsourcing facilities to compound these agents.
• If finalised, the rule would bar 503B facilities from compounding any of these GLP-1 peptides under any circumstances — including in the event of a future shortage designation.
• 503A patient-specific compounding pharmacies are not directly affected by this proposal, but remain separately constrained by the "essentially a copy" prohibition.
• A public comment period is open until 29 June 2026 via Federal Register docket FDA-2026-N-0817.
• The proposal is backed by adverse event data, with the FDA having received more than 455 reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide.

Background: what the 503B Bulks List is, and why it matters

To understand the significance of this proposal, it is necessary to understand the 503B framework established under the Federal Food, Drug, and Cosmetic Act.

Section 503B of the FD&C Act governs outsourcing facilities — FDA-registered entities that manufacture compounded drugs in large batches, typically for healthcare institutions rather than individual patients. Unlike 503A compounding pharmacies (which are primarily regulated by state pharmacy boards and produce drugs pursuant to individual prescriptions), 503B facilities operate on a scale closer to pharmaceutical manufacturing.

Under the 503B framework, outsourcing facilities may only use bulk drug substances if the substance is on the bulks list or the compounded drug is on the shortage list. With neither condition currently met for semaglutide or tirzepatide — both were removed from the FDA's drug shortage list in 2025 — the significance of this proposal is that it would close one of the few remaining legal avenues for 503B outsourcing facilities to resume large-scale compounding of these drugs.

What the FDA proposed, and when

On 30 April 2026, the FDA announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances. The notice was published in the Federal Register on 1 May 2026 (91 Fed. Reg. 23431).

The three substances at issue map onto the most commercially significant GLP-1 receptor agonists currently on the market. Semaglutide is FDA-approved under the brand names Wegovy, Ozempic, and Rybelsus. Tirzepatide is approved as Mounjaro and Zepbound. Liraglutide is approved as Saxenda and Victoza.

The agency's stated rationale was categorical: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need," FDA Commissioner Marty Makary said in the agency's announcement. Notably, the FDA explicitly rejected affordability and insurance access as constituting clinical need under this statutory framework — a significant clarification given that cost arguments have been central to the compounding sector's advocacy position.

How the compounded GLP-1 industry developed and then contracted

The proposal represents the latest step in a regulatory trajectory that began with acute drug shortages in 2022. Semaglutide products were added to the FDA's drug shortage list in 2022 and removed in 2025. Tirzepatide was added in 2022 and removed in 2024.

During the shortage period, demand-driven compounding at 503B facilities expanded considerably. Compounded versions ran approximately $150 to $300 per month, against branded list prices north of $1,000 per month, and at peak in 2024, compounded GLP-1s accounted for around 30% of total US GLP-1 supply.

As shortages resolved, the FDA escalated its enforcement posture progressively. The Outsourcing Facilities Association filed federal lawsuits challenging both the tirzepatide and semaglutide shortage removals, but courts denied preliminary injunctions in each case, and the enforcement deadlines held. In March 2026, the FDA issued 30 warning letters to telehealth companies marketing compounded GLP-1 products whose promotion implied equivalence to FDA-approved products. The 30 April proposal is the formalisation of that posture into a structural, prospective rule.

Safety data underpinning the proposal

Patient safety evidence featured prominently in the agency's reasoning. As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials — some of which required hospitalisation. The Partnership for Safe Medicines noted that mass compounding of GLP-1 medications has been linked to hundreds of adverse events — including sepsis, liver injury, and hospitalisations — as well as recalls involving thousands of contaminated or improperly dosed vials.

Who is affected and who is not

The proposal's scope is limited to the 503B pathway. The proposal does not impact 503A pharmacies, which make compounded drugs according to individual prescriptions for a specific patient and are largely regulated by states rather than the FDA. However, 503A pharmacies are not straightforwardly unaffected. The removal of semaglutide and tirzepatide from the FDA's drug shortage list in 2025 already eliminated the primary legal basis that had permitted 503A pharmacies to compound drugs that are "essentially a copy" of commercially available branded products. 503A pharmacies wishing to continue compounding these molecules therefore need to demonstrate a clinically justified deviation from the commercial product — for example, a meaningfully different dose form, strength, or delivery route — rather than simple cost-based substitution.

If the proposal is finalised, 503B outsourcing facilities will be unable to compound semaglutide, tirzepatide, or liraglutide from bulk drug substances, as neither the 503B bulks list nor the drug shortage list would authorise such activity. Legal analysts at Orrick note that the litigation risk environment has intensified dramatically for any facility continuing to source and compound these APIs.

What happens during the comment period

The FDA is inviting interested parties to submit comments electronically through the federal docket by 29 June 2026, and the agency will consider submitted comments before making a final determination. The National Community Pharmacists Association and the Alliance for Pharmacy Compounding are expected to file comments opposing the exclusion.

It is worth noting that a separate regulatory track is running in parallel: the FDA is simultaneously considering the addition of certain peptide active ingredients not found in any FDA-approved drug — including compounds on the Category 2 list such as BPC-157 and Thymosin Alpha-1 — to bulk ingredient lists ahead of the Pharmacy Compounding Advisory Committee meetings scheduled for July 2026. These processes are legally and procedurally distinct, although they share the same underlying statutory framework.

Implications for UK research procurement

The 503B closure does not directly affect UK or EU research supply chains, where semaglutide and tirzepatide are separately regulated by the MHRA and EMA respectively. However, the tightening US framework has measurable indirect effects:

• API sourcing: Large-volume peptide API that previously flowed to US 503B compounders may find alternative export markets, potentially affecting international wholesale price benchmarks.
• Reference standards: Analytical reference standards for semaglutide and tirzepatide — used in HPLC purity testing and mass spectrometry confirmation — remain freely available for legitimate research purposes, but procurement teams should anticipate evolving documentation requirements from suppliers seeking to demonstrate compliance with US customers.
• Market precedent: The FDA's stated position that affordability does not constitute clinical need may influence MHRA and EMA policy thinking in future reviews of peptide compounding frameworks in the UK and EU.

What to watch

The comment period closes 29 June 2026. A final rule is unlikely before late 2026 at the earliest, given the volume of anticipated comments. Courts may also be asked to weigh in by the Outsourcing Facilities Association, whose prior injunction attempts have failed. For the present, neither semaglutide, tirzepatide, nor liraglutide appears on either the 503B Bulks List or the FDA drug shortage list, meaning large-scale 503B compounding of these substances is already without legal authority regardless of the proposal's outcome.